{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:03:47Z","timestamp":1786493027721,"version":"build-2736575974"},"reference-count":85,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1136\/ard.2006.052761","type":"journal-article","created":{"date-parts":[[2006,8,2]],"date-time":"2006-08-02T07:42:42Z","timestamp":1154504562000},"page":"1406-1413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Experience with experimental biological treatment and local gene therapy in Sj\u00f6gren's syndrome: implications for exocrine pathogenesis and treatment"],"prefix":"10.1016","volume":"65","author":[{"given":"B M","family":"Lodde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B J","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P P","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Illei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2006.052761_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/154411130201300103","article-title":"Progress in understanding autoimmune exocrinopathy using the non-obese diabetic mouse: an update","volume":"13","author":"Cha","year":"2002","journal-title":"Crit Rev Oral Biol Med"},{"key":"10.1136\/ard.2006.052761_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1385\/CRIAI:25:1:89","article-title":"Immunopathogenesis of Sjogren\u00e2\u20ac\u2122s syndrome","volume":"25","author":"Borchers","year":"2003","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1136\/ard.2006.052761_bib3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1006\/clin.1994.1123","article-title":"Sjogren\u00e2\u20ac\u2122s syndrome: autoimmune epithelitis","volume":"72","author":"Moutsopoulos","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"issue":"Suppl 1","key":"10.1136\/ard.2006.052761_bib4","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0003-9969(99)90008-0","article-title":"New concepts for the development of autoimmune exocrinopathy derived from studies with the NOD mouse model","volume":"44","author":"Humphreys-Beher","year":"1999","journal-title":"Arch Oral Biol"},{"key":"10.1136\/ard.2006.052761_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/sarh.2003.50019","article-title":"Apoptosis and Sjogren syndrome","volume":"33","author":"Manganelli","year":"2003","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard.2006.052761_bib6","doi-asserted-by":"crossref","unstructured":"Fox RI, Stern M. Sjogren\u00e2\u20ac\u2122s syndrome: mechanisms of pathogenesis involve interaction of immune and neurosecretory systems. Scand J Rheumatol Suppl 2002:3\u201313.","DOI":"10.1080\/030097402317474874"},{"key":"10.1136\/ard.2006.052761_bib7","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/ard.62.8.702","article-title":"Parasympathetic nervous system dysfunction in primary Sjogren\u00e2\u20ac\u2122s syndrome","volume":"62","author":"Hocevar","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.052761_bib8","first-page":"143","article-title":"Outcome measures for Sjogren\u00e2\u20ac\u2122s syndrome, April 10-11, 2003, Bethesda, Maryland, USA","volume":"32","author":"Pillemer","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.052761_bib9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ddmec.2004.11.014","article-title":"Disease mechanisms of Sj\u00c3\u00b6gren\u00e2\u20ac\u2122s syndrome","volume":"1","author":"Delaleu","year":"2004","journal-title":"Drug Discov Today Dis Mech"},{"key":"10.1136\/ard.2006.052761_bib10","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/ard.2004.031781","article-title":"Salivary gland and peripheral blood T helper 1 and 2 cell activity in Sjogren\u00e2\u20ac\u2122s syndrome compared with non-Sjogren\u00e2\u20ac\u2122s sicca syndrome","volume":"64","author":"van Woerkom","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.052761_bib11","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/ard.2005.040956","article-title":"Th2 cytokine genotypes are associated with a milder form of primary Sjogren\u00e2\u20ac\u2122s syndrome","volume":"65","author":"Pertovaara","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.052761_bib12","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1046\/j.1365-2249.2002.01869.x","article-title":"The Th1\/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren\u00e2\u20ac\u2122s syndrome","volume":"128","author":"Mitsias","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1136\/ard.2006.052761_bib13","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/art.21006","article-title":"Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren\u00e2\u20ac\u2122s syndrome patients from healthy control subjects","volume":"52","author":"Hjelmervik","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.052761_bib14","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1073\/pnas.0510837103","article-title":"Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren\u00e2\u20ac\u2122s syndrome","volume":"103","author":"Gottenberg","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1136\/ard.2006.052761_bib15","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1172\/JCI3234","article-title":"Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren\u00e2\u20ac\u2122s syndrome","volume":"102","author":"Stott","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1136\/ard.2006.052761_bib16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/ard.62.2.168","article-title":"The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren\u00e2\u20ac\u2122s syndrome","volume":"62","author":"Mariette","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.052761_bib17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1196\/annals.1313.004","article-title":"BAFF overexpression is associated with autoantibody production in autoimmune diseases","volume":"1050","author":"Pers","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1136\/ard.2006.052761_bib18","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-3083.2005.01688.x","article-title":"The BAFF\/APRIL system in systemic autoimmune diseases with a special emphasis on Sjogren\u00e2\u20ac\u2122s syndrome","volume":"62","author":"Szodoray","year":"2005","journal-title":"Scand J Immunol"},{"key":"10.1136\/ard.2006.052761_bib19","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/ard.62.11.1038","article-title":"Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjogren\u00e2\u20ac\u2122s syndrome","volume":"62","author":"Kok","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.052761_bib20","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1517\/14712598.5.6.763","article-title":"Gene therapeutics in Sjogren\u00e2\u20ac\u2122s syndrome","volume":"5","author":"Bolstad","year":"2005","journal-title":"Expert Opin Biol Ther"},{"key":"10.1136\/ard.2006.052761_bib21","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1089\/104454902762053855","article-title":"Adenovirus and adeno-associated virus vectors","volume":"21","author":"Lai","year":"2002","journal-title":"DNA Cell Biol"},{"key":"10.1136\/ard.2006.052761_bib22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0074-7696(02)13013-0","article-title":"Gene transfer to salivary glands","volume":"213","author":"Baum","year":"2002","journal-title":"Int Rev Cytol"},{"key":"10.1136\/ard.2006.052761_bib23","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJM200406103502422","article-title":"LMO2 and gene therapy for severe combined immunodeficiency","volume":"350","author":"Fischer","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2006.052761_bib24","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1517\/14712598.4.7.1093","article-title":"Recombinant adeno-associated virus vectors for gene therapy","volume":"4","author":"Conlon","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"10.1136\/ard.2006.052761_bib25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1006\/clim.2002.5189","article-title":"Pathogenesis of Sjogren\u00e2\u20ac\u2122s syndrome: characteristics of different mouse models for autoimmune exocrinopathy","volume":"103","author":"van Blokland","year":"2002","journal-title":"Clin Immunol"},{"key":"10.1136\/ard.2006.052761_bib26","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1089\/104303403322542257","article-title":"Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjogren\u00e2\u20ac\u2122s syndrome","volume":"14","author":"Kok","year":"2003","journal-title":"Hum Gene Ther"},{"key":"10.1136\/ard.2006.052761_bib27","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/08916930400021352","article-title":"Non-depleting anti-CD4 antibody not only prevents onset but resolves sialadenitis in NOD mice","volume":"37","author":"Thompson","year":"2004","journal-title":"Autoimmunity"},{"key":"10.1136\/ard.2006.052761_bib28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0896-8411(03)00044-1","article-title":"The complex role of interleukin-10 in autoimmunity","volume":"20","author":"Groux","year":"2003","journal-title":"J Autoimmun"},{"key":"10.1136\/ard.2006.052761_bib29","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1167\/iovs.03-0755","article-title":"Prophylactic effect of IL-10 gene transfer on induced autoimmune dacryoadenitis","volume":"45","author":"Zhu","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1136\/ard.2006.052761_bib30","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.4049\/jimmunol.162.5.2488","article-title":"Fas ligand-mediated exocrinopathy resembling Sjogren\u00e2\u20ac\u2122s syndrome in mice transgenic for IL-10","volume":"162","author":"Saito","year":"1999","journal-title":"J Immunol"},{"key":"10.1136\/ard.2006.052761_bib31","first-page":"411","article-title":"Circulating levels of Th1\/Th2 cytokines in patients with primary Sjogren\u00e2\u20ac\u2122s syndrome: correlation with clinical and immunological features","volume":"19","author":"Garcic-Carrasco","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2006.052761_bib33","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/art.1780390816","article-title":"Cytokine messenger RNA expression in the labial salivary glands of patients with Sjogren\u00e2\u20ac\u2122s syndrome","volume":"39","author":"Ohyama","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.052761_bib34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/08916939808996281","article-title":"Differential cytokine mRNA expression in human labial minor salivary glands in primary Sjogren\u00e2\u20ac\u2122s syndrome","volume":"28","author":"Sun","year":"1998","journal-title":"Autoimmunity"},{"key":"10.1136\/ard.2006.052761_bib35","first-page":"131","article-title":"Tumor necrosis factor-alpha and receptors for it in labial salivary glands in Sjogren\u00e2\u20ac\u2122s syndrome","volume":"19","author":"Koski","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2006.052761_bib36","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00003226-200305000-00012","article-title":"Tumor necrosis factor inhibitor gene expression suppresses lacrimal gland immunopathology in a rabbit model of autoimmune dacryoadenitis","volume":"22","author":"Zhu","year":"2003","journal-title":"Cornea"},{"key":"10.1136\/ard.2006.052761_bib37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1740-2557-2-6","article-title":"Expression of TNF inhibitor gene in the lacrimal gland promotes recovery of tear production and tear stability and reduced immunopathology in rabbits with induced autoimmune dacryoadenitis","volume":"2","author":"Trousdale","year":"2005","journal-title":"J Autoimmune Dis"},{"key":"10.1136\/ard.2006.052761_bib38","series-title":"Proceedings of the Annual Meeting American College of Rheumatology","first-page":"1120","article-title":"Disease modifying effects of local tumor necrosis factor alpha receptor gene transfer in a murine model of Sj\u00c3\u00b6gren\u00e2\u20ac\u2122s syndrome [abstract]","author":"Kok","year":"2004"},{"key":"10.1136\/ard.2006.052761_bib39","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF03348097","article-title":"Vasoactive intestinal peptide","volume":"9","author":"Said","year":"1986","journal-title":"J Endocrinol Invest"},{"key":"10.1136\/ard.2006.052761_bib40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/ard.2005.038232","article-title":"Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren\u00e2\u20ac\u2122s syndrome","volume":"65","author":"Lodde","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.052761_bib41","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.4049\/jimmunol.162.3.1707","article-title":"Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies","volume":"162","author":"Delgado","year":"1999","journal-title":"J Immunol"},{"key":"10.1136\/ard.2006.052761_bib42","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1096\/fj.03-1440hyp","article-title":"The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide?","volume":"18","author":"Pozo","year":"2004","journal-title":"FASEB J"},{"key":"10.1136\/ard.2006.052761_bib43","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.immunol.18.1.621","article-title":"Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity","volume":"18","author":"Karin","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"10.1136\/ard.2006.052761_bib44","doi-asserted-by":"crossref","first-page":"12819","DOI":"10.1074\/jbc.M312572200","article-title":"A p105-based inhibitor broadly represses NF-kappa B activities","volume":"279","author":"Fu","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1136\/ard.2006.052761_bib45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI11830","article-title":"NF-kappaB: a key role in inflammatory diseases","volume":"107","author":"Tak","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1136\/ard.2006.052761_bib46","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1002\/art.11352","article-title":"Development of autoimmune exocrinopathy resembling Sjogren\u00e2\u20ac\u2122s syndrome in adoptively transferred mice with autoreactive CD4+ T cells","volume":"48","author":"Arakaki","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.052761_bib47","first-page":"2157","article-title":"Prevalence of antibodies against alpha-fodrin in Sjogren\u00e2\u20ac\u2122s syndrome: comparison of 2 sets of classification criteria","volume":"30","author":"Witte","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.052761_bib48","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1568-9972(03)00002-8","article-title":"Antibodies against alpha-fodrin in Sjogren\u00e2\u20ac\u2122s syndrome","volume":"2","author":"Ulbricht","year":"2003","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard.2006.052761_bib50","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1002\/art.20472","article-title":"Effective treatment of a mouse model of Sjogren\u00e2\u20ac\u2122s syndrome with eyedrop administration of anti-CD4 monoclonal antibody","volume":"50","author":"Hayashi","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.052761_bib51","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11882-005-0077-x","article-title":"Recent advances in the management of ocular complications of Sjogren\u00e2\u20ac\u2122s syndrome","volume":"5","author":"Samarkos","year":"2005","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1136\/ard.2006.052761_bib52","first-page":"101","article-title":"Improvement of lacrimal function by topical application of CyA in murine models of Sjogren\u00e2\u20ac\u2122s syndrome","volume":"42","author":"Tsubota","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1136\/ard.2006.052761_bib53","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/01.ico.0000133994.22392.47","article-title":"Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca","volume":"24","author":"Strong","year":"2005","journal-title":"Cornea"},{"key":"10.1136\/ard.2006.052761_bib54","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/art.1780400113","article-title":"Fas and Fas ligand expression in the salivary glands of patients with primary Sjogren\u00e2\u20ac\u2122s syndrome","volume":"40","author":"Kong","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.052761_bib55","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/clin.1998.4556","article-title":"Bcl-2 family expression in salivary glands from patients with primary Sjogren\u00e2\u20ac\u2122s syndrome: involvement of Bax in salivary gland destruction","volume":"88","author":"Kong","year":"1998","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1136\/ard.2006.052761_bib56","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/1529-0131(200104)44:4<964::AID-ANR154>3.0.CO;2-5","article-title":"Treatment of chronic sialadenitis in a murine model of Sjogren\u00e2\u20ac\u2122s syndrome by local fasL gene transfer","volume":"44","author":"Fleck","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.052761_bib57","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/1529-0131(199812)41:12<2175::AID-ART12>3.0.CO;2-I","article-title":"Murine cytomegalovirus induces a Sjogren\u00e2\u20ac\u2122s syndrome-like disease in C57Bl\/6-lpr\/lpr mice","volume":"41","author":"Fleck","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.052761_bib58","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/(SICI)1097-4652(199605)167:2<297::AID-JCP14>3.0.CO;2-5","article-title":"Interferon-gamma induced cell death in a cultured human salivary gland cell line","volume":"167","author":"Wu","year":"1996","journal-title":"J Cell Physiol"},{"key":"10.1136\/ard.2006.052761_bib59","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.tibtech.2005.01.009","article-title":"Immune modulation for prevention of type 1 diabetes mellitus","volume":"23","author":"Raz","year":"2005","journal-title":"Trends Biotechnol"},{"key":"10.1136\/ard.2006.052761_bib60","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0167-5699(90)90057-G","article-title":"The genetics and epidemiology of diabetes in NOD mice","volume":"11","author":"Leiter","year":"1990","journal-title":"Immunol Today"},{"key":"10.1136\/ard.2006.052761_bib61","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/08916939108997125","article-title":"High and low diabetes incidence nonobese diabetic (NOD) mice: origins and characterisation","volume":"9","author":"Baxter","year":"1991","journal-title":"Autoimmunity"},{"key":"10.1136\/ard.2006.052761_bib62","first-page":"386","article-title":"Increased incidence of diabetes mellitus in specific pathogen-eliminated offspring produced by embryo transfer in NOD mice with low incidence of the disease","volume":"44","author":"Ohsugi","year":"1994","journal-title":"Lab Anim Sci"},{"key":"10.1136\/ard.2006.052761_bib63","unstructured":"Lodde BM, Mineshiba F, Kok MR, Wang J, Zheng C, Schmidt M, et al. NOD mouse model for Sj\u00c3\u00b6gren\u00e2\u20ac\u2122s Syndrome: lack of longitudinal stability. Oral diseases. In press."},{"key":"10.1136\/ard.2006.052761_bib64","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/1529-0131(200110)44:10<2371::AID-ART401>3.0.CO;2-W","article-title":"Infliximab in patients with primary Sjogren\u00e2\u20ac\u2122s syndrome: a pilot study","volume":"44","author":"Steinfeld","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.052761_bib65","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1002\/art.10674","article-title":"Infliximab in primary Sjogren\u00e2\u20ac\u2122s syndrome: one-year followup","volume":"46","author":"Steinfeld","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.052761_bib66","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sjogren\u00e2\u20ac\u2122s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren\u00e2\u20ac\u2122s Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.052761_bib67","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sjogren\u00e2\u20ac\u2122s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.052761_bib68","first-page":"96","article-title":"Etanercept in the treatment of patients with primary Sjogren\u00e2\u20ac\u2122s syndrome: a pilot study","volume":"31","author":"Zandbelt","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.052761_bib69","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/art.20416","article-title":"Prominent adverse effects of thalidomide in primary Sjogren\u00e2\u20ac\u2122s syndrome","volume":"51","author":"Pillemer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.052761_bib70","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/art.1780271006","article-title":"Thalidomide. A promising new treatment for rheumatoid arthritis","volume":"27","author":"Gutierrez-Rodriguez","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.052761_bib71","first-page":"2344","article-title":"Thalidomide in the treatment of refractory rheumatoid arthritis","volume":"26","author":"Keesal","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.052761_bib72","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/art.11199","article-title":"Treatment of primary Sjogren\u00e2\u20ac\u2122s syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results","volume":"49","author":"Cummins","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.052761_bib73","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/art.20998","article-title":"Activation of the type I interferon system in primary Sjogren\u00e2\u20ac\u2122s syndrome: a possible etiopathogenic mechanism","volume":"52","author":"B\u00c3\u00a5ve","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.052761_bib74","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1089\/107999099313479","article-title":"Interferon-alpha upregulates gene expression of aquaporin-5 in human parotid glands","volume":"19","author":"Smith","year":"1999","journal-title":"J Interferon Cytokine Res"},{"key":"10.1136\/ard.2006.052761_bib75","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1136\/ard.2006.052761_bib76","first-page":"90","article-title":"Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A","volume":"42","author":"Brignole","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1136\/ard.2006.052761_bib77","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/ard.2004.025676","article-title":"Primary Sjogren\u00e2\u20ac\u2122s syndrome: new clinical and therapeutic concepts","volume":"64","author":"Ramos-Casals","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.052761_bib78","doi-asserted-by":"crossref","first-page":"888","DOI":"10.7326\/0003-4819-89-6-888","article-title":"Increased risk of lymphoma in sicca syndrome","volume":"89","author":"Kassan","year":"1978","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2006.052761_bib79","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sjogren\u00e2\u20ac\u2122s syndrome: an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.052761_bib80","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","article-title":"Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases","volume":"64","author":"Gottenberg","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.052761_bib81","series-title":"Proceedings of the Annual Meeting of the American College of Rheumatology","first-page":"681","article-title":"Epratuzumab (anti-CD22) for the treatment of primary Sj\u00c3\u00b6gren\u00e2\u20ac\u2122s syndrome [abstract]","author":"Steinfeld","year":"2005"},{"key":"10.1136\/ard.2006.052761_bib82","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.270.5234.286","article-title":"Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis","volume":"270","author":"Auphan","year":"1995","journal-title":"Science"},{"key":"10.1136\/ard.2006.052761_bib83","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0165-5728(00)00297-6","article-title":"Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors","volume":"109","author":"De Bosscher","year":"2000","journal-title":"J Neuroimmunol"},{"key":"10.1136\/ard.2006.052761_bib84","first-page":"149","article-title":"Prednisone and piroxicam for treatment of primary Sjogren\u00e2\u20ac\u2122s syndrome","volume":"11","author":"Fox","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2006.052761_bib85","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/ard.57.8.464","article-title":"Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sjogren\u00e2\u20ac\u2122s syndrome","volume":"57","author":"Izumi","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.052761_bib32","first-page":"1874","article-title":"Interleukin 10 (IL-10) influences autoimmune response in primary Sjogren\u00e2\u20ac\u2122s syndrome and is linked to IL-10 gene polymorphism","volume":"29","author":"Anaya","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.052761_bib49","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1002\/(SICI)1521-4141(199810)28:10<3336::AID-IMMU3336>3.0.CO;2-R","article-title":"Anti-120-kDa alpha-fodrin immune response with Th1-cytokine profile in the NOD mouse model of Sjogren\u00e2\u20ac\u2122s syndrome","volume":"28","author":"Yanagi","year":"1998","journal-title":"Eur J Immunol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724199827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724199827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2006.052761","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T14:25:13Z","timestamp":1736087113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724199827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":85,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S0003496724199827"],"URL":"https:\/\/doi.org\/10.1136\/ard.2006.052761","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experience with experimental biological treatment and local gene therapy in Sj\u00f6gren's syndrome: implications for exocrine pathogenesis and treatment","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2006.052761","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Copyright 2006 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}